Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein
- PMID: 2327990
- PMCID: PMC1131247
- DOI: 10.1042/bj2670079
Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein
Abstract
The characteristics of a new kallikrein-binding protein in human serum and its activities were studied. Both the kallikrein-binding protein and alpha 1-antitrypsin form 92 kDa SDS-stable and heat-stable complexes with human tissue kallikrein. In non-SDS/PAGE, the mobility of these complexes differ. Complex-formation between kallikrein and the binding protein is inhibited by heparin, whereas that between kallikrein and alpha 1-antitrypsin is heparin-resistant. In normal or alpha 1-antitrypsin-deficient-serum, the amount of 92 kDa SDS-stable complex formed upon addition of kallikrein is not related to serum alpha 1-antitrypsin levels. The rate of complex-formation between kallikrein and the binding protein is 12 times higher than that between kallikrein and alpha 1-antitrypsin. Purified alpha 1-antitrypsin, which exhibits normal elastase binding, has a kallikrein-binding activity less than 5% of that of serum. Binding of tissue kallikrein in serum is not inhibited by increasing elastase concentrations, and elastase binding in serum is not inhibited by excess tissue kallikrein. A specific monoclonal antibody to human alpha 1-antitrypsin does not bind to either 92 kDa endogenous or exogenous kallikrein complexes isolated from human serum. The studies demonstrate a new tissue kallikrein-binding protein, distinct from alpha 1-antitrypsin, is present in human serum.
Similar articles
-
Identification of a new tissue-kallikrein-binding protein.Biochem J. 1986 Oct 15;239(2):325-31. doi: 10.1042/bj2390325. Biochem J. 1986. PMID: 3643793 Free PMC article.
-
Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence.J Biol Chem. 1992 Dec 25;267(36):25873-80. J Biol Chem. 1992. PMID: 1334488
-
A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein.J Biol Chem. 2000 Dec 22;275(51):40371-7. doi: 10.1074/jbc.M005691200. J Biol Chem. 2000. PMID: 10991942
-
Tissue kallikrein inhibitors in mammals.Immunopharmacology. 1996 May;32(1-3):67-72. doi: 10.1016/0162-3109(96)00010-0. Immunopharmacology. 1996. PMID: 8796269 Review.
-
Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.Biochemistry. 1989 Nov 14;28(23):8951-66. doi: 10.1021/bi00449a001. Biochemistry. 1989. PMID: 2690952 Review. No abstract available.
Cited by
-
Protective Role of Kallistatin in Vascular and Organ Injury.Hypertension. 2016 Sep;68(3):533-41. doi: 10.1161/HYPERTENSIONAHA.116.07861. Epub 2016 Jul 18. Hypertension. 2016. PMID: 27432868 Free PMC article. Review.
-
Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids.Biochem J. 1999 Apr 15;339 ( Pt 2)(Pt 2):473-9. Biochem J. 1999. PMID: 10191281 Free PMC article.
-
Expression and characterization of rat kallikrein-binding protein in Escherichia coli.Biochem J. 1993 Jun 15;292 ( Pt 3)(Pt 3):825-32. doi: 10.1042/bj2920825. Biochem J. 1993. PMID: 8318011 Free PMC article.
-
Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin.Antimicrob Agents Chemother. 2015 Sep;59(9):5619-30. doi: 10.1128/AAC.00065-15. Epub 2015 Jul 6. Antimicrob Agents Chemother. 2015. PMID: 26149981 Free PMC article.
-
Elevated tissue kallikrein activity in airway secretions from patients with tracheobronchitis associated with prolonged mechanical ventilation.Lung. 2003;181(5):237-44. doi: 10.1007/s00408-003-1019-9. Lung. 2003. PMID: 14705767
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources